Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. The Norwegian EBBA Study

  • Anne-Sofie Furberg
    1Institute of Community Medicine, Faculty of Medicine, University of Tromsø;
  • Grazyna Jasienska
    3Department of Epidemiology and Population Studies, Institute of Public Health, Jagiellonian University, Krakow, Poland;
  • Nils Bjurstam
    2Department of Radiology, Centre of Breast Imaging, University Hospital of North Norway, Tromsø, Norway;
  • Peter A. Torjesen
    4Hormone Laboratory, Aker and the
  • Aina Emaus
    1Institute of Community Medicine, Faculty of Medicine, University of Tromsø;
  • Susan F. Lipson
    6Department of Anthropology, Harvard University, Cambridge, Massachusetts
  • Peter T. Ellison
    6Department of Anthropology, Harvard University, Cambridge, Massachusetts
  • Inger Thune
    1Institute of Community Medicine, Faculty of Medicine, University of Tromsø;

書誌事項

公開日
2005-01-01
DOI
  • 10.1158/1055-9965.33.14.1
公開者
American Association for Cancer Research (AACR)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>Low serum high-density lipoprotein cholesterol (HDL-C) is an important component of the metabolic syndrome and has recently been related to increased breast cancer risk in overweight and obese women. We therefore questioned whether serum HDL-C might be a biologically sound marker of breast cancer risk. We obtained cross-sectional data among 206 healthy women ages 25 to 35 years who participated in the Norwegian EBBA study. We included salivary ovarian steroid concentrations assessed by daily samples throughout one entire menstrual cycle, metabolic profile with measures of adiposity [body mass index (BMI) and truncal fat percentage], serum concentrations of lipids and hormones (insulin, leptin, testosterone, dehydroepiandrostendione sulfate, insulin-like growth factor-I, and its principal binding protein), and mammographic parenchymal pattern. We examined how components of the metabolic syndrome, including low serum HDL-C, were related to levels of hormones, and free estradiol concentration in particular, and studied predictors of mammographic parenchymal patterns in regression models. In women with BMI ≥ 23.6 kg/m2 (median), overall average salivary estradiol concentration dropped by 2.4 pmol/L (0.7 pg/mL; 13.2% change in mean for the total population) by each 0.33 mmol/L (12.8 mg/dl; 1SD) increase in serum HDL-C (P = 0.03; Pinteraction = 0.03). A subgroup of women characterized by both relatively high BMI (≥23.6 kg/m2) and high serum LDL-C/HDL-C ratio (≥ 2.08; 75 percentile) had substantially higher levels of salivary estradiol by cycle day than other women (P = 0.001). BMI was the strongest predictor of overall average estradiol with a direct relationship (P&lt; 0.001). Serum HDL-C was inversely related to serum leptin, insulin, and dehydroepiandrostendione sulfate (P &lt; 0.001, P &lt; 0.01, and P &lt; 0.05, respectively). There was a direct relationship between breast density and healthy metabolic profiles (low BMI, high serum HDL-C; P &lt; 0.001) and salivary progesterone concentrations (P &lt; 0.05). Our findings support the hypothesis that low serum HDL-C might reflect an unfavorable hormonal profile with, in particular, increased levels of estrogens and gives further clues to biomarkers of breast cancer risk especially in overweight and obese women.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ